Pro‐ and anti‐inflammatory cytokine associations with major depression in cancer patients

Cytokines may be linked to depression, although it has been challenging to demonstrate this association in cancer because of the overlap between depressive symptoms and other sickness behaviors. This study investigates the relationship between cytokines and depression in cancer patients, accounting for confounding clinical and methodological factors.

[1]  F. Lotrich.  Inflammatory cytokine-associated depression , 2015, Brain Research.

[2]  S. Ahrendt,et al.  Preoperative inflammatory biomarkers and neurovegetative symptoms in peritoneal carcinomatosis patients , 2014, Brain, Behavior, and Immunity.

[3]  J. Wolchok,et al.  Depression, cytokines, and pancreatic cancer , 2014, Psycho-oncology.

[4]  A. Ochiai,et al.  Associations of interleukin-6 with vegetative but not affective depressive symptoms in terminally ill cancer patients , 2013, Supportive Care in Cancer.

[5]  D. F. Drake,et al.  Dopaminergic mechanisms of reduced basal ganglia responses to hedonic reward during interferon alfa administration. , 2012, Archives of general psychiatry.

[6]  R. Ho,et al.  Interleukin (IL)-6, tumour necrosis factor alpha (TNF-α) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. , 2012, Journal of Affective Disorders.

[7]  Madeline Li,et al.  Evidence-based treatment of depression in patients with cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Peisong Chen,et al.  Emerging tendency towards autoimmune process in major depressive patients: A novel insight from Th17 cells , 2011, Psychiatry Research.

[9]  N. Meader,et al.  Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. , 2011, The Lancet. Oncology.

[10]  N. Herrmann,et al.  A Meta-Analysis of Cytokines in Major Depression , 2010, Biological Psychiatry.

[11]  Philip D. Harvey,et al.  Does cytokine-induced depression differ from idiopathic major depression in medically healthy individuals? , 2009, Journal of affective disorders.

[12]  Jennifer L Martin,et al.  To assess, to control, to exclude: Effects of biobehavioral factors on circulating inflammatory markers , 2009, Brain, Behavior, and Immunity.

[13]  W. Breitbart,et al.  Measuring Depression at the End of Life , 2009, Assessment.

[14]  J. Suls,et al.  Associations of Depression With C-Reactive Protein, IL-1, and IL-6: A Meta-Analysis , 2009, Psychosomatic medicine.

[15]  F. Penedo,et al.  Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Biondi,et al.  Differences in depressive thoughts between major depressive disorder, IFN-alpha-induced depression, and depressive disorders among cancer patients. , 2008, Journal of psychosomatic research.

[17]  J. Olin,et al.  The GRID-HAMD: standardization of the Hamilton Depression Rating Scale , 2008, International clinical psychopharmacology.

[18]  D. Hopko,et al.  The Phenomenology and Screening of Clinical Depression in Cancer Patients , 2007, Journal of psychosocial oncology.

[19]  Henrik Ahlenius,et al.  Tumor Necrosis Factor Receptor 1 Is a Negative Regulator of Progenitor Proliferation in Adult Hippocampal Neurogenesis , 2006, The Journal of Neuroscience.

[20]  Michael Marriott,et al.  Lower hippocampal volume in patients suffering from depression: a meta-analysis. , 2004, The American journal of psychiatry.

[21]  F. Verhey,et al.  Disease-specific properties of the Hamilton Rating Scale for Depression in patients with stroke, Alzheimer's dementia, and Parkinson's disease , 2002 .

[22]  C. Nemeroff,et al.  Neurobehavioral Effects of Interferon-α in Cancer Patients: Phenomenology and Paroxetine Responsiveness of Symptom Dimensions , 2002, Neuropsychopharmacology.

[23]  A K Manatunga,et al.  Paroxetine for the prevention of depression induced by high-dose interferon alfa. , 2001, The New England journal of medicine.

[24]  M. Hamilton.  A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.

[25]  Madeline Li,et al.  52 – Depression and anxiety in supportive oncology , 2011 .

[26]  P. Buckley,et al.  Neuroendocrine-Immune Mechanisms of Behavioral Comorbidities in Patients With Cancer , 2009 .

[27]  F. Verhey,et al.  Disease-specific properties of the Rating Scale for Depression in patients with stroke, Alzheimer's dementia, and Parkinson's disease. , 2002, The Journal of neuropsychiatry and clinical neurosciences.

[28]  D. Sheehan,et al.  The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. , 1998, The Journal of clinical psychiatry.

[29]  M. Talpaz,et al.  Treatment of neurotoxic side effects of interferon-alpha with naltrexone. , 1995, Cancer investigation.

[30]  A. Valentine,et al.  Treatment of Neurotoxic Side Effects of Interferon-α with Naltrexone , 1995 .